Porsolt continues to play a significant role in research collaborations as demonstrated with the following paper just published by #Sunovion in the journal “Drug and Alcohol Dependence”.
Preclinical drug abuse and liability studies “suggest that the TAAR1/5-HT1A agonist ulotaront is not likely to pose a risk for recreational abuse in humans and may have potential therapeutic utility as a treatment of substance use disorders”.
To read the paper: https://lnkd.in/gz5gSe5V
Contact@porsolt.com
www.porsolt.com
